An Improved
211At
PSMA
murine models
prostate cancer
radiopharmaceutical therapy
α-emitter
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
06
02
2021
revised:
05
05
2021
pubmed:
6
6
2021
medline:
30
4
2022
entrez:
5
6
2021
Statut:
ppublish
Résumé
α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved effective in treating patients with prostate cancer who were unresponsive to the corresponding β-particle therapy.
Identifiants
pubmed: 34088772
pii: jnumed.121.262098
doi: 10.2967/jnumed.121.262098
pmc: PMC8805774
doi:
Substances chimiques
Antigens, Surface
0
Radiopharmaceuticals
0
Lutetium
5H0DOZ21UJ
Glutamate Carboxypeptidase II
EC 3.4.17.21
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
259-267Subventions
Organisme : NIBIB NIH HHS
ID : P41 EB024495
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA134675
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184228
Pays : United States
Informations de copyright
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2545-2557
pubmed: 31399803
J Labelled Comp Radiopharm. 2018 Mar;61(3):154-164
pubmed: 29080397
Cancers (Basel). 2020 May 26;12(6):
pubmed: 32466595
J Nucl Med. 2016 Oct;57(10):1569-1575
pubmed: 27230930
Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1280-92
pubmed: 24577951
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1081-1091
pubmed: 30603987
Bioconjug Chem. 2011 Aug 17;22(8):1700-5
pubmed: 21740058
J Nucl Med. 2007 Jul;48(7):1190-6
pubmed: 17574991
J Med Chem. 1996 Jan 19;39(2):619-22
pubmed: 8558536
Curr Radiopharm. 2018;11(3):200-208
pubmed: 29732998
Nucl Med Biol. 2021 Mar-Apr;94-95:67-80
pubmed: 33601187
Med Phys. 2004 Feb;31(2):218-25
pubmed: 15000607
Nucl Med Biol. 1998 May;25(4):351-7
pubmed: 9639296
Eur Urol. 2021 Mar;79(3):343-350
pubmed: 33293081
Curr Radiopharm. 2008 Sep 1;1(3):177
pubmed: 20150978
J Nucl Med. 2020 Jan;61(1):62-69
pubmed: 31101746
Clin Cancer Res. 2020 Jun 15;26(12):2946-2955
pubmed: 31932492
Cancer Biother Radiopharm. 2013 Feb;28(1):1-20
pubmed: 23075373
J Nucl Med. 2021 Jul 1;62(7):980-988
pubmed: 33246975
Pharmaceuticals (Basel). 2015 Jun 10;8(2):321-36
pubmed: 26066613
Cancer Res. 1999 Jul 1;59(13):3192-8
pubmed: 10397265
J Nucl Med. 2015 Sep;56(9):1401-1407
pubmed: 26182968
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Theranostics. 2020 Jul 23;10(20):9364-9377
pubmed: 32802197
Molecules. 2018 Mar 05;23(3):
pubmed: 29510568
J Nucl Med. 2001 Oct;42(10):1508-15
pubmed: 11585865
J Nucl Med. 2016 Aug;57(8):1170-6
pubmed: 26985056
Bioorg Med Chem. 2012 Dec 15;20(24):6929-39
pubmed: 23159039
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
Phys Med. 2018 Jul;51:91-98
pubmed: 29807854
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
J Nucl Med. 2020 Jan;61(1):80-88
pubmed: 31253744
Semin Radiat Oncol. 2021 Jan;31(1):71-82
pubmed: 33246638
J Med Chem. 2009 Jan 22;52(2):347-57
pubmed: 19111054
Cancer Biother Radiopharm. 2020 Aug;35(6):425-436
pubmed: 32077749
Prostate. 2020 Nov;80(15):1273-1296
pubmed: 32865839
Clin Cancer Res. 2020 Apr 15;26(8):1985-1996
pubmed: 31831560
Mol Imaging. 2002 Apr-Jun;1(2):96-101
pubmed: 12920850
EJNMMI Res. 2020 Feb 11;10(1):10
pubmed: 32048062
J Nucl Med. 2021 May 10;62(5):669-674
pubmed: 33008928
Curr Radiopharm. 2011 Jul;4(3):177-85
pubmed: 22201707
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1262-1263
pubmed: 32959114